HONG KONG – Onquality Pharmaceuticals LLC raised an additional $20 million from a series A+ financing round, bringing its amount of capital raised to $35 million.

Speaking during the 2021 China Pharmaceutical Innovation 100 Summit, industry insiders called for more regulatory talent and even an organizational revamp to clear innovative products faster and support the global development strategies of Chinese drugmakers.

SHANGHAI – China’s regulatory environment has evolved to encourage drug innovation, but despite remarkable progress, mounting pricing pressure from the government and a weak insurance sector remain as barriers.

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Airway, Antengene, Beigene, Biontech, Cansino, Cytodyn, Gan & Lee, Generex, Huyabio, Immutep, Junshi, Mitoimmune, Nugenerex Immuno-Oncology, Pfizer, Resverlogix.

New hires and promotions in the biopharma industry in Asia-Pacific, including: Inmagene Biopharmaceuticals.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: ABL, Aim Immunotech, Akston, Algernon, Antengene, Astrazeneca, Azurrx, Beigene, Bridge, Cytodyn, Daiichi Sankyo, Dynavax, Eli Lilly, I-Mab, Immunitybio, Incyte, Kiniksa, Laurent, Molecular Partners, Neurorx, Novartis, Novavax, Redhill, Regeneron, Relief, Roche, Union, Valneva.

Biopharmas in Asia-Pacific raising money in public or private financings, including: ACM, Bionomics, Delta 4, Humanigen, Hutchison China Meditech, Icosavax.

With less uncertainty surrounding the pandemic, the biopharma industry appears on track to shift efforts back to its internal programs and possibly meet, if not exceed, the record-breaking deal level of 2020. Strong financial markets, however, may continue to hold M&As down.